

PUBBLICAZIONI

- 1: Di Micco P, Imbalzano E, Russo V, Attena E, Mandaliti V, Orlando L, Lombardi M, Di Micco G, Camporese G, Annunziata S, Piccinocchi G, Pacelli W, Del Guercio M. Heparin and SARS-CoV-2: Multiple Pathophysiological Links. *Viruses*. 2021 Dec 11;13(12):2486. doi: 10.3390/v13122486. PMID: 34960754; PMCID: PMC8705068.
- 2: Bottino R, Carbone A, Liccardo B, Imbalzano E, D'Andrea A, Russo V. Optimal anticoagulation in patients with atrial fibrillation and bioprosthetic heart valves. *Kardiol Pol*. 2022;80(2):137-150. doi: 10.33963/KP.a2022.0051. PMID: 35235996.
- 3: Russo V, Fabiani D. Put out the fire: The pleiotropic anti-inflammatory action of non-vitamin K oral anticoagulants. *Pharmacol Res*. 2022 Aug;182:106335. doi: 10.1016/j.phrs.2022.106335. Epub 2022 Jun 30. PMID: 35781059.
- 4: Renon F, Rago A, Liccardo B, D'Andrea A, Riegler L, Golino P, Nigro G, Russo V. Direct Oral Anticoagulants Plasma Levels Measurement: Clinical Usefulness from Trials and Real-World Data. *Semin Thromb Hemost*. 2021 Mar;47(2):150-160. doi: 10.1055/s-0041-1723770. Epub 2021 Feb 26. PMID: 33636746.
- 5: Bottino R, Carbone A, Liccardo B, D'Andrea A, Rago A, Papa AA, Spaccarotella C, Golino P, Nigro G, Russo V. Edoxaban (LIXIANA[®]) in the treatment of venous thromboembolism. *Future Cardiol*. 2021 Aug;17(5):779-791. doi: 10.2217/fca-2020-0139. Epub 2020 Nov 24. PMID: 33231106.
- 6: Russo V, Proietti R, Lodigiani C, Di Micco P. Fondaparinux and bleeding risk in COVID-19: unsolved question. *Thromb Res*. 2021 Apr;200:128-129. doi: 10.1016/j.thromres.2021.01.025. Epub 2021 Feb 9. PMID: 33592530; PMCID: PMC7870442.
- 7: Russo V, Bottino R, D'Andrea A, Silverio A, Di Maio M, Golino P, Nigro G, Valsecchi O, Attena E, Canonico ME, Galasso G, Parodi G, Scudiero F. Chronic Oral Anticoagulation and Clinical Outcome in Hospitalized COVID-19 Patients. *Cardiovasc Drugs Ther*. 2022 Aug;36(4):705-712. doi: 10.1007/s10557-021-07194-y. Epub 2021 May 14. PMID: 33988835; PMCID: PMC8120255.
- 8: Russo V, Caputo A, Imbalzano E, Di Micco P, Frontera A, Uccello A, Orlando L, Galimberti P, Golino P, D'Andrea A. The pharmacology of anticoagulant drug treatment options in COVID-19 patients: reviewing real-world evidence in clinical practice. *Expert Rev Clin Pharmacol*. 2022 Sep;15(9):1095-1105. doi: 10.1080/17512433.2022.2117154. Epub 2022 Sep 6. PMID: 36017645.
- 9: Russo V, Silverio A, Scudiero F, Micco PD, Maio MD. Pre-admission atrial fibrillation in COVID-19 patients: Prevalence and clinical impact. *Eur J Intern Med*. 2021 Jun;88:133-135. doi: 10.1016/j.ejim.2021.03.017. Epub 2021 Mar 19. PMID: 33810938; PMCID: PMC7972716.
- 10: Carbone A, Santelli F, Bottino R, Attena E, Mazzone C, Parisi V, D'Andrea A, Golino P, Nigro G, Russo V. Prevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octagenarians with atrial fibrillation. *Eur J Clin Pharmacol*. 2022 May;78(5):879-886. doi: 10.1007/s00228-022-03286-2. Epub 2022 Feb 9. PMID: 35138442; PMCID: PMC9005392.
- 11: Langella V, Bottino R, Asti A, Maresca G, Di Palma G, Pomponi D, Sassone C, Imbalzano E, Russo V. Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients. *Expert Rev Clin Pharmacol*. 2021 Oct;14(10):1289-1294. doi: 10.1080/17512433.2021.1964359. Epub 2021 Aug 17. PMID: 34402362; PMCID: PMC8425471.
- 12: Vio R, Giordani AS, Stefil M, Alturki A, Russo V, China P, Gasperetti A, Schiavone M, Čulić V, Biondi-Zoccai G, Themistoclakis S, Yh Lip G, Proietti R. Therapeutic vs. prophylactic anticoagulation in COVID-19 patients: a systematic review and meta-analysis of real-world studies. *Minerva Cardiol Angiol*. 2022 Dec;70(6):652-662. doi: 10.23736/S2724-5683.22.06230-5. Epub 2022 Oct 28. PMID: 36305780.
- 13: Patti G, Parato VM, Cavallari I, Calabrò P, Russo V, Renda G, Gragnano F, Pengo V, D'Onofrio A, Grimaldi M, De Caterina R. A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation. *J Clin Med*. 2022 Mar 31;11(7):1945. doi: 10.3390/jcm11071945. PMID: 35407553; PMCID: PMC8999540.
- 14: Lavalle C, Mariani MV, Piro A, Magnocavallo M, Vetta G, Trivigno S, Forleo GB, Della Rocca DG, Ugucioni M, Russo V, Summaria F, Di Lullo L. Five Years of Direct Oral Anticoagulants Use in Italy: Adverse Drug Reactions from the Italian National Pharmacovigilance Network. *J Clin Med*. 2022 Jun 4;11(11):3207. doi: 10.3390/jcm11113207. PMID: 35683593; PMCID: PMC9181424.
- 15: Imbalzano E, Orlando L, Sciacqua A, Nato G, Dentali F, Nassisi V, Russo V, Camporese G, Bagnato G, Cicero AFG, Dattilo G, Vatrano M, Versace AG, Squadrito G, Di Micco P. Machine Learning to Calculate Heparin Dose in COVID-19 Patients with Active Cancer. *J Clin Med*. 2021 Dec 31;11(1):219. doi: 10.3390/jcm11010219. PMID: 35011959; PMCID: PMC8746167.

- 16: Russo V, Attena E, Baroni M, Trotta R, Manu MC, Kirchof P, De Caterina R. Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries. *J Clin Med*. 2022 Jun 28;11(13):3751. doi: 10.3390/jcm11133751. PMID: 35807032; PMCID: PMC9267647.
- 17: Russo V, Cattaneo D, Giannetti L, Bottino R, Laezza N, Atripaldi U, Clementi E. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity. *Clin Ther*. 2021 Sep;43(9):e255-e263. doi: 10.1016/j.clinthera.2021.07.003. Epub 2021 Aug 6. PMID: 34366151.
- 18: Carbone A, Bottino R, Attena E, Parisi V, Conte M, D'Andrea A, Imbalzano E, Golino P, Russo V. Clinical impact of oral anticoagulation among octogenarians with atrial fibrillation and anaemia. *J Thromb Thrombolysis*. 2023 Feb;55(2):222-227. doi: 10.1007/s11239-022-02740-3. Epub 2022 Dec 6. PMID: 36472719.
- 19: Di Micco P, Tufano A, Cardillo G, Imbalzano E, Amitrano M, Lodigiani C, Bellizzi A, Camporese G, Cavalli A, De Stefano C, Russo V, Voza A, Perrella A, Prandoni P. The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study. *Viruses*. 2021 Aug 30;13(9):1720. doi: 10.3390/v13091720. PMID: 34578301; PMCID: PMC8473366.
- 20: Rago A, Pezzullo E, Malvezzi Caracciolo d'Aquino M, Scognamiglio G, Caso VM, Martone F, Attena E, Parisi V, D'Onofrio A, Golino P, Nigro G, Russo V. Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study. *J Blood Med*. 2021 Jun 4;12:413-420. doi: 10.2147/JBM.S299265. PMID: 34113202; PMCID: PMC8187032.
- 21: Rago A, Papa AA, Attena E, Parisi V, Golino P, Nigro G, Russo V. Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score-Matched Study. *Cardiovasc Drugs Ther*. 2021 Oct;35(5):1003-1007. doi: 10.1007/s10557-020-07078-7. Epub 2020 Sep 18. PMID: 32946035; PMCID: PMC8452548.